[{"orgOrder":0,"company":"Grifols International","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Grifols International \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ BARDA"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"VCN Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2021","type":"Acquisition","leadProduct":"Gemcitabine","moa":"||Tumor stroma","graph1":"Oncology","graph2":"Phase I","graph3":"Grifols International","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Intratumoral Infusion","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"6","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Albumin","moa":"Bilirubin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"11","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Antibody-protein Conjugate","year":"2020","type":"Inapplicable","leadProduct":"IVIG-PEG","moa":"Immunoglobulins","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hyperimmune Immunoglobulin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ National Institutes of Health"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Perflutren","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Tianjin Tiancheng Pharma. Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"BT524","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Grifols International","amount2":1.28,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":1.28,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"BT524","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prolastin-C","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prolastin-C","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Hyperimmune Globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Human Normal Immunoglobulin","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Albumin","moa":"Bilirubin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Prolastin","moa":"Leukocyte elastase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Antithrombin III","moa":"Serine protease","graph1":"Hematology","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Alkahest","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GRF6021","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"GIGA-2050","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"GigaGen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"GIGA-2050","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"6","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Selagine","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"GRF312","moa":"Cytokine","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"5","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Selagine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"SLG-100","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"1","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"15","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Savara","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Grifols International \/ Savara","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Savara"},{"orgOrder":0,"company":"Grifols International","sponsor":"Aradigm","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Grifols International","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Inhalation","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Soleo Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Immune Globulin (Human)","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"15","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Immune Globulin, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"FVIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"11","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prolastin-C","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"C19-IG","moa":"IgG","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Perflutren","moa":"||blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Human Normal Immunoglobulin","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Endpoint Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Antithrombin III","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Grifols International","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Endpoint Health","highestDevelopmentStatusID":"4","companyTruncated":"Grifols International \/ Endpoint Health"},{"orgOrder":0,"company":"Grifols International","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Grifols International \/ BARDA"},{"orgOrder":0,"company":"Grifols International","sponsor":"Alkahest","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Grifols International","amount2":0.14999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"2","companyTruncated":"Grifols International \/ Grifols International"}]
Find Clinical Drug Pipeline Developments & Deals by Grifols International
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
